Alamea Verwaltungs GmbH bought a new stake in Xylem Inc. (NYSE:XYL - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 5,438 shares of the industrial products company's stock, valued at approximately $650,000. Xylem comprises about 0.6% of Alamea Verwaltungs GmbH's holdings, making the stock its 23rd largest position.
A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Xylem by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 29,006,544 shares of the industrial products company's stock valued at $3,465,122,000 after buying an additional 362,127 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Xylem by 7.9% in the 4th quarter. Royal Bank of Canada now owns 4,369,804 shares of the industrial products company's stock valued at $506,985,000 after purchasing an additional 320,500 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Xylem by 8.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,750,377 shares of the industrial products company's stock valued at $435,119,000 after purchasing an additional 301,070 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Xylem by 689.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,708,963 shares of the industrial products company's stock valued at $443,074,000 after purchasing an additional 3,239,203 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Xylem by 2.9% in the 1st quarter. Northern Trust Corp now owns 3,362,993 shares of the industrial products company's stock valued at $401,743,000 after purchasing an additional 94,560 shares during the period. 87.96% of the stock is owned by hedge funds and other institutional investors.
Xylem Stock Performance
Xylem stock traded up $2.14 during mid-day trading on Thursday, reaching $141.84. 786,877 shares of the company were exchanged, compared to its average volume of 1,445,709. Xylem Inc. has a twelve month low of $100.47 and a twelve month high of $145.33. The firm's 50-day simple moving average is $136.87 and its two-hundred day simple moving average is $127.08. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.43 and a current ratio of 1.90. The firm has a market cap of $34.52 billion, a PE ratio of 36.84, a price-to-earnings-growth ratio of 2.45 and a beta of 1.09.
Xylem (NYSE:XYL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The industrial products company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.15 by $0.11. Xylem had a return on equity of 10.33% and a net margin of 10.74%.The company had revenue of $2.30 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same period last year, the firm earned $1.09 EPS. The firm's revenue for the quarter was up 6.1% on a year-over-year basis. Xylem has set its FY 2025 guidance at 4.700-4.850 EPS. Equities analysts predict that Xylem Inc. will post 4.65 earnings per share for the current fiscal year.
Xylem Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 25th. Shareholders of record on Thursday, August 28th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, August 28th. This represents a $1.60 annualized dividend and a yield of 1.1%. Xylem's payout ratio is presently 41.56%.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the company. Raymond James Financial raised Xylem to a "hold" rating in a research report on Thursday, May 15th. Citigroup reissued a "buy" rating and issued a $152.00 target price (up from $137.00) on shares of Xylem in a research report on Monday, July 14th. JPMorgan Chase & Co. assumed coverage on Xylem in a research report on Friday, May 30th. They issued an "overweight" rating and a $148.00 target price for the company. Wall Street Zen raised Xylem from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, UBS Group upped their target price on Xylem from $164.00 to $168.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $152.29.
Read Our Latest Stock Analysis on Xylem
Xylem Profile
(
Free Report)
Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.
See Also

Before you consider Xylem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.
While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.